浓缩自体骨髓抽吸物在骨不连和骨缺损修复中并非“干细胞”疗法。
Concentrated autologous bone marrow aspirate is not "stem cell" therapy in the repair of nonunions and bone defects.
作者信息
Goodman Stuart B, Zwingenberger Stefan
机构信息
Departments of Orthopaedic Surgery and Bioengineering, Stanford University, Stanford CA, USA.
University Center of Orthopaedic, Trauma and Plastic Surgery, University Hospital Carl Gustav Carus at Technische Universität Dresden, Dresden, Germany.
出版信息
Biomater Biosyst. 2021 Apr 8;2:100017. doi: 10.1016/j.bbiosy.2021.100017. eCollection 2021 Jun.
Autogenous bone grafting is the gold standard for replacing large bone defects. Due to limitations in the quantity and quality of harvested bone from the iliac crest, and the potential associated morbidity, the technique of cell grafting has been developed. Autogenous bone marrow aspirate is concentrated (so called BMAC) and delivered locally to the intended site with minimally invasive techniques. However, there are only about 1 in 30,000 Colony Forming Unit-Fibroblast (CFU-F) progenitor cells in unconcentrated iliac crest aspirate. Current techniques for cell concentration only increase these numbers by about 5-fold. Thus, BMAC is not equivalent to "stem cell therapy".
自体骨移植是修复大的骨缺损的金标准。由于取自髂嵴的骨在数量和质量上存在局限性，以及潜在的相关发病率，细胞移植技术应运而生。自体骨髓抽吸物被浓缩（即所谓的BMAC），并通过微创技术局部输送到预期部位。然而，未浓缩的髂嵴抽吸物中每30000个细胞中只有约1个集落形成单位成纤维细胞（CFU-F）祖细胞。目前的细胞浓缩技术仅使这些数量增加约5倍。因此，BMAC并不等同于“干细胞疗法”。
Zotero 插件